Side-effect concerns dampen AZ/Ardelyx's first-in-class drug promise
This article was originally published in Scrip
Executive Summary
A Phase IIb study of Ardelyx's selective NHE3 inhibitor tempanor has thrown up a side-effect concern in one of its potential indications, hyperphosphatemia. Shares in the firm dropped by 29% to close at $19.25 on Nasdaq on 2 February.